معرفی
Dr. Kevin Damman is a Clinical Professor and Cardiologist at the University Medical Center Groningen (UMCG), affiliated with the Faculty of Medical Sciences at the University of Groningen. He leads the heart transplant and left ventricular assist device program, focusing on advanced heart failure and cardiorenal interactions. His research emphasizes improving acute heart failure treatments, including SGLT2 inhibitors and diuretic therapy optimization. He holds editorial roles at the European Journal of Heart Failure and chairs the MCS Working Group of the Netherlands Society of Cardiology. Dr. Damman is a co-investigator in pivotal studies like EMPA-RESPONSE-AHF and ADVOR, exploring novel therapies in heart failure.
His research spans acute heart failure pathophysiology, cardiorenal syndrome, and translational medicine through initiatives like the TransplantLines biobank. He contributes to clinical guidelines on diuretic titration and natriuresis monitoring. Dr. Damman actively participates in international working groups (ESC HFA) and registries (EUROMACS), shaping global standards in heart failure care. His work bridges clinical practice and research, aiming to enhance patient outcomes through innovative therapies and precision medicine approaches.
Grants and studies include leadership roles in the PUSH-AHF and ADVOR trials, investigating decongestive therapies and acetazolamide respectively. He collaborates with multidisciplinary teams across Europe, emphasizing the integration of renal function assessment into heart failure management strategies. Dr. Damman’s contributions extend to public engagement through expert commentary on high-profile transplant cases and emerging treatments in cardiovascular medicine.
